title: [Pharmaco-economic efficiency of the treatment of patients with acute vertebrogenic lumbar pain syndrome].
abstract: The aim of the study was to evaluate pharmaco-economic efficiency of two therapeutic schemes for the treatment of acute vertebrogenic lumbar pain syndrome. One hundred patients (including 77 women) with this syndrome caused by vertebral osteochondrosis (VO) were examined. Mean age of the patients was 41.00 +/- 8.33, mean duration of exacerbation 6.92 +/- 4.55 days. The majority of the patients had roentgenologic stage II VO. Patients of one group (n=50) were given intramuscular injections of ketorol (1 ml twice daily for 5 days) and diclofenac-retard (100 mg per os twice daily for 10 days). The second group (n=50) received ketorol and nise (100 mg twice daily for 10 days). This treatment was followed by 10 seances of phonophoresis using 1% hydrocortisone ointment. The clinical efficiency of therapy was evaluated based on the visual analog scale and in terms of Lasagne symptom, muscular syndrome index, Schober test, Thomayer's symptom, vertebrogenic syndrome coefficient. Pharmaco-economic analysis included calculation of direct medical care expenses and cost index/efficiency. The efficiency of therapy in group 2 (restoration of lumbar vertebral column mobility and alleviation of pain) was higher than in group 1 while the number of adverse effects was lower and the periods of remission longer. Combined therapy with ketorol and nise per unit efficiency was more expensive but the total cost of the management of one case including all yearly relapses suggested its advantages over the alternative treatment with ketorol and diclofenacin terms of clinical and pharmaco-economic efficiency.
authors.forename: T V
authors.initials: TV
authors.lastname: Chernysheva
authors.forename: G G
authors.initials: GG
authors.lastname: Bagirova
mesh_terms: D000208:Acute Disease; D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000191:economics; D001416:Back Pain / Q000188:drug therapy* / Q000191:economics*; D003362:Cost-Benefit Analysis; D004008:Diclofenac / Q000008:administration & dosage* / Q000191:economics; D004180:Direct Service Costs; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage / Q000191:economics; D006801:Humans; D006854:Hydrocortisone / Q000008:administration & dosage* / Q000191:economics; D007273:Injections, Intramuscular; D020910:Ketorolac / Q000008:administration & dosage* / Q000191:economics; D008297:Male; D008875:Middle Aged; D009824:Ointments; D010147:Pain Measurement; D015612:Phonophoresis / Q000191:economics / Q000379:methods; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D005938:Glucocorticoids; D009824:Ointments; D004008:Diclofenac; D006854:Hydrocortisone; D020910:Ketorolac